

Supplementary Appendix 3: Clinical characteristics of 126 hemodialysis patients receiving the BNT162b2 or mRNA-1273 COVID-19 vaccine with serology at both 6-7 weeks and 12 weeks

Characteristic	No. (%) of hemodialysis patients*		p value
	BNT162b2 n=63	mRNA-1273 n=63	
Age, yr; median (IQR)	73 (64-81)	59 (54-67)	<0.001
Male sex	36 (57.1%)	43 (68.3%)	0.2
Previous COVID-19 [†]	3 (4.8%)	4 (6.3%)	0.7
Comorbidity			
Prior solid-organ transplant	0 (0%)	16 (25.4%)	<0.001
Immunosuppressive treatment [‡]	3 (4.8%)	12 (19.0%)	0.013
Diabetes mellitus	39 (61.9%)	22 (34.9%)	0.002
Coronary artery disease	28 (44.4%)	10 (15.9%)	<0.001
Congestive heart failure	19 (30.2%)	14 (22.2%)	0.3
Cerebrovascular disease	13 (20.6%)	5 (7.9%)	0.04
Hypertension	58 (92.1%)	54 (85.7%)	0.26

Note: COVID-19=coronavirus-19, IQR=interquartile range.

*Unless stated otherwise.

[†]Confirmed by reverse-transcription-polymerase chain reaction at study enrollment.

[‡]Defined as taking any of the following: antimetabolite agent, calcineurin inhibitor, cytotoxic medications, rituximab in prior 6 months, tumor necrosis factor alpha monoclonal antibodies, glucocorticoids at a dosage of more than prednisone 5 mg daily, or active chemotherapy.